

UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO. **FILING DATE** FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 09/027,777 02/23/98 IMMER Н P1614-8019 **EXAMINER** HM12/0824 NIKAIDO MARMELSTEIN MURRAY & ORAM VANDER VEGT, F METROPOLITAN SQUARE PAPER NUMBER **ART UNIT** 655 FIFTEENTH STREET N W SUITE 330 G STREET LOBBY 1644 WASHINGTON DC 20005-5701 **DATE MAILED:** 08/24/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



Office Action Summary

Application No. 09/027,777

Ap. it(s)

Immer et al

Examiner

F. Pierre VanderVegt

Group Art Unit 1644



Responsive to communication(s) filed on Apr 10, 2000	<u> </u>
☐ This action is FINAL.	
☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is close in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.	
A shortened statutory period for response to this action is so is longer, from the mailing date of this communication. Failuapplication to become abandoned. (35 U.S.C. § 133). Exte 37 CFR 1.136(a).	
Disposition of Claim	
	js/are pending in the application.
Of the above, claim(s) 21-27	je/are withdrawn from consideration.
☐ Claim(s)	is/are allowed.
	∕s/are rejected.
Claim(s)	is/are objected to.
	are subject to restriction or election requirement.
Application Papers See the attached Notice of Draftsperson's Patent Draw The drawing(s) filed on	bjected to by the Examiner. is approved disapproved. r. rity under 35 U.S.C. § 119(a)-(d). es of the priority documents have been Number) the International Bureau (PCT Rule 17.2(a)).
Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Pape Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review, PTO Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION O	ON THE FOLLOWING PAGES

Application/Control Number: 09/027,777

Art Unit: 1644

Page 2

DETAILED ACTION

This application is a divisional of application S.N. 08/737,927 which is a rule 371 continuation of PCT/EP95/02050.

Claims 21-33 are currently pending in this application.

5

10

15

20

Election/Restriction

- Applicant's election without traverse of Group II, claims 28-33, in Paper No. is 1. acknowledged.
- 2. Claims 21-27 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in Paper No. 18.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office Action:

A person shall be entitled to a patent unless --

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the Applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (f) he did not himself invent the subject matter sought to be patented.
- Claims 28-33 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by U.S. 3. Patent No. 4,751,284 to Forssmann (A on form PTO-892).

The '284 patent teaches cardiodilatin and fragments thereof. Specifically, claim 1 of the '284 patent is drawn to full length cardiodilatin and claim 2 is drawn to biologically active fragments thereof. More specifically, claim 28 of the '284 patent is drawn to a cardiodilatin fragment which is the same as the ANP(99-126) peptide instantly disclosed and specifically

claimed [instant claim 31]. Therefore, claim 28 of the '284 patent specifically teaches the

25

Application/Control Number: 09/027,777

Art Unit: 1644

Page 3

cardiodilatin fragments of the instantly claimed invention where R¹ is 99-104 [instant claim 29], R² is 122-126 [30] which are fragments of 90-104 and 122-126 [28], respectively, wherein said fragments are attached to a core which is the same as SEQ ID NO:1. Applicant is reminded that the recitation of "having" in claim 33 is considered open terminology and therefore includes longer amino acid sequences which "have" the recited sequence contained therein. The prior art teaching clearly anticipates the claimed invention.

4. Claims 28-33 are rejected under 35 U.S.C. 102(a) as being clearly anticipated by U.S. Patent No. 5,449,751 to Forssmann et al (AA on form PTO-1449).

10

15

5

The '751 patent teaches the cardiodilatin fragment R¹-ANP(105-121)-R² wherein R¹ is ANP(95-104) [instant claim 29] and R² is ANP(122-126) (Abstract and claim 1 of the '751 patent in particular). The '751 patent additionally teaches the fragments of amino acids 99-126 (column 1, line 6 in particular) and 95-125 (column 9, line 36 in particular) as well as pharmaceutical compositions (medicaments; column 3, lines 37-61 in particular). Applicant is reminded that the recitation of "having" in claim 33 is considered open terminology and therefore includes longer amino acid sequences which "have" the recited sequence contained therein. The prior art teaching clearly anticipates the claimed invention.

5. Claims 28-33 are rejected under 35 U.S.C. 102(f) because the Applicant did not invent the claimed subject matter.

U.S. Patent No. 4,751,284 (A) has been discussed supra. The '284 patent discloses that the instantly claimed subject matter was invented in its entirety by Wolf-Georg Forssmann (see entire document). Therefore, Hansueli Immer, Knut Adermann and Christian Klessen are not inventors of the instantly claimed invention.

25

Conclusion

6. Papers related to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. Papers should be faxed to Group 1640 via the PTO Fax Center

Application/Control Number: 09/027,777

Art Unit: 1644

5

10

15

Page 4

located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The fax phone number for official documents to be entered into the record for Art Unit 1644 is (703)305-3014.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to F. Pierre VanderVegt, whose telephone number is (703)305-6997. The Examiner can normally be reached Tuesday through Friday and odd-numbered Mondays (on year 2000 366-day calender) from 6:30 am to 4:00 pm ET. A message may be left on the Examiner's voice mail service. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ms. Christina Chan can be reached at (703)308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist, whose telephone number is (703)308-0196.

F. Pierre VanderVegt, Ph.D. Patent Examiner Technology Center 1600 July 10, 2000

PIERRE VANDERVEGT PATENT EXAMINER